Moleculin reports 37% blinded CRc in MIRACLE trial; venetoclax-failed subgroup similar

Moleculin Biotech, Inc.

Preliminary blinded CRc of 37% and CR of 24% in 62 evaluable R/R AML subjects.
Among 30 patients who failed prior venetoclax, CRc also 37% (3x published salvage rate of ~13%).
No cardiotoxicity observed; enrollment at 74 of 90; final Part A treatment expected Sept 2026.
Unblinded Part A results expected Dec 2026–Feb 2027; prior unblinded Annamycin arms showed CRc 50-57% vs control 29%.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.